Newsletter | January 10, 2022

01.10.22 -- Innovation And Integrated Solutions For Advanced Therapeutics

Manufacturing Innovation Across New Modalities

The successful outcomes delivered by cell and gene therapies, coupled with the emergence of modalities across nucleic acid therapeutics and microbiomes, pose the next scalability challenge.

Unprecedented Growth — And Challenges — In Gene Therapy

The gene therapy clinical pipeline is in a high-growth phase, with an influx of venture capital funding. There are also challenges: scalability, dosing, and the price of the final treatment.

Allogeneic T-Cell Therapies: Efficient Commercial Manufacturing Readiness

A rationale-based methodology to address T-cell manufacturing challenges, based on the intended final manufacturing process, proposes a robust, scalable, cost-effective, and sustainable allogeneic platform.

Integrated Solutions For Advanced Therapeutics

Our development expertise across all gene therapy modalities (adeno-associated virus [AAV], lentivirus, oncolytic virus, etc.) and proven clinical through commercial scale-up capabilities will provide full life cycle support of your life-saving therapeutic.

Request Information